Log in
NASDAQ:XNCR

Xencor Stock Forecast, Price & News

$43.02
+0.90 (+2.14 %)
(As of 09/18/2020 12:00 AM ET)
Add
Compare
Today's Range
$41.62
Now: $43.02
$43.90
50-Day Range
$30.09
MA: $34.48
$42.12
52-Week Range
$19.35
Now: $43.02
$43.90
Volume2.24 million shs
Average Volume431,099 shs
Market Capitalization$2.46 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.94
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions. The company's product candidates include XmAb5871, an immune inhibitor, which has been completed Phase II clinical trial for the treatment of autoimmune diseases; and XmAb7195, an immune inhibitor that has been completed Phase I clinical trial for the treatment of asthma and allergic diseases. Its product candidates also comprise XmAb14045, a bispecific oncology candidate, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; XmAb13676 that is in Phase I clinical trial to treat B-cell malignancies; and XmAb18087, which is in Phase I clinical trial for neuroendocrine tumors and gastrointestinal stromal tumors. In addition, the company offers MOR208, an antibody drug that is in Phase III clinical trial to treat non-Hodgkin lymphomas, as well as in Phase II clinical trial for chronic lymphocytic leukemia; AMG424, a bispecific antibody that targets CD38 and CD3, which is in Phase I clinical trial for the treatment of various myeloma; and AMG50, a bispecific antibody that is in preclinical development stage to treat prostate cancer. Further, it is developing bispecific antibodies to treat various cancers, such as XmAb20717, XmAb22841, XmAb23104, and XmAb24306 which are in preclinical Phase. The company has collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc.; MorphoSys Ag; Amgen Inc.; and Catalent Pharma Solutions LLC. Xencor, Inc. was founded in 1997 and is headquartered in Monrovia, California.
Read More
Xencor logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.3Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.98 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:XNCR
CUSIPN/A
Phone626-305-5900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$156.70 million
Cash Flow$0.58 per share
Book Value$10.46 per share

Profitability

Net Income$26.88 million
Net Margins-113.40%

Miscellaneous

Employees156
Market Cap$2.46 billion
Next Earnings Date11/3/2020 (Estimated)
OptionableOptionable
$43.02
+0.90 (+2.14 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive XNCR News and Ratings via Email

Sign-up to receive the latest news and ratings for XNCR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Xencor (NASDAQ:XNCR) Frequently Asked Questions

How has Xencor's stock price been impacted by Coronavirus?

Xencor's stock was trading at $28.12 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, XNCR shares have increased by 53.0% and is now trading at $43.02.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Xencor?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xencor in the last year. There are currently 2 sell ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Xencor
.

When is Xencor's next earnings date?

Xencor is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Xencor
.

How were Xencor's earnings last quarter?

Xencor Inc (NASDAQ:XNCR) released its quarterly earnings data on Tuesday, August, 4th. The biopharmaceutical company reported ($0.61) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.56) by $0.05. The biopharmaceutical company earned $13.09 million during the quarter, compared to analysts' expectations of $9.12 million. Xencor had a negative net margin of 113.40% and a negative return on equity of 13.56%.
View Xencor's earnings history
.

What price target have analysts set for XNCR?

8 brokers have issued twelve-month price targets for Xencor's stock. Their forecasts range from $21.00 to $52.00. On average, they expect Xencor's share price to reach $40.63 in the next twelve months. This suggests that the stock has a possible downside of 5.6%.
View analysts' price targets for Xencor
.

Who are some of Xencor's key competitors?

What other stocks do shareholders of Xencor own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Xencor investors own include Intelsat (I), Bank of America (BAC), Cypress Semiconductor (CY), Apollo Global Management (APO), NVIDIA (NVDA), AbbVie (ABBV), AMC Entertainment (AMC), Exelixis (EXEL), Fossil Group (FOSL) and Intel (INTC).

Who are Xencor's key executives?

Xencor's management team includes the following people:
  • Dr. Bassil I. Dahiyat Ph.D., Co-Founder, CEO, Pres & Director (Age 49)
  • Mr. John J. Kuch, Sr. VP of Fin., CFO & Sec. (Age 60)
  • Dr. John R. Desjarlais, Sr. VP of Research & Chief Scientific Officer (Age 55)
  • Dr. Paul A. Foster, Sr. VP & Chief Medical Officer (Age 65)
  • Mr. Charles Liles, Associate Director and Head of Corp. Communications & Investor Relations

What is Xencor's stock symbol?

Xencor trades on the NASDAQ under the ticker symbol "XNCR."

Who are Xencor's major shareholders?

Xencor's stock is owned by a variety of institutional and retail investors. Top institutional investors include FMR LLC (14.94%), Vanguard Group Inc. (10.08%), BVF Inc. IL (3.61%), Goldman Sachs Group Inc. (1.58%), Bank of New York Mellon Corp (0.98%) and Candriam Luxembourg S.C.A. (0.81%). Company insiders that own Xencor stock include John J Kuch, John R Desjarlais, John S Stafford III and Ronin Capital, Llc.
View institutional ownership trends for Xencor
.

Which institutional investors are selling Xencor stock?

XNCR stock was sold by a variety of institutional investors in the last quarter, including Federated Hermes Inc., UBS Group AG, Rhenman & Partners Asset Management AB, WINTON GROUP Ltd, Mutual of America Capital Management LLC, Barclays PLC, Great West Life Assurance Co. Can, and Smith Asset Management Group LP. Company insiders that have sold Xencor company stock in the last year include John S Stafford III, and Ronin Capital, Llc.
View insider buying and selling activity for Xencor
.

Which institutional investors are buying Xencor stock?

XNCR stock was purchased by a variety of institutional investors in the last quarter, including BVF Inc. IL, Vanguard Group Inc., Goldman Sachs Group Inc., Candriam Luxembourg S.C.A., Man Group plc, Marshall Wace North America L.P., Prudential Financial Inc., and Marshall Wace LLP.
View insider buying and selling activity for Xencor
.

How do I buy shares of Xencor?

Shares of XNCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Xencor's stock price today?

One share of XNCR stock can currently be purchased for approximately $43.02.

How big of a company is Xencor?

Xencor has a market capitalization of $2.46 billion and generates $156.70 million in revenue each year. The biopharmaceutical company earns $26.88 million in net income (profit) each year or $0.46 on an earnings per share basis. Xencor employs 156 workers across the globe.

What is Xencor's official website?

The official website for Xencor is www.xencor.com.

How can I contact Xencor?

Xencor's mailing address is 111 WEST LEMON AVENUE, MONROVIA CA, 91016. The biopharmaceutical company can be reached via phone at 626-305-5900 or via email at [email protected]

This page was last updated on 9/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.